Created at Source Raw Value Validated value
April 14, 2021, 2:05 p.m. oms

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group X: Two-dose 10-ug youth (18-59 years) group and two-dose 25-ug youth (18-59 years) group:All the subjects are administrated V-01 or placebo on Days 0 and Day 21 at the deltoid muscle in the upper arm and tested for safety; tolerance and immunogenicity as per the schedule described in the study protocol.;Group Y: Two-dose 10-ug elder (>=60 years) group and two-dose 25-ug elder (>=60 years) group:All the subjects are administrated V-01 or placebo on Days 0 and Day 21 at the deltoid muscle in the upper arm and tested for safety; tolerance and immunogenicity as per the schedule described in the study protocol.;Group Z: One-dose 50-ug youth (18-59 years) group:All the subjects are administrated V-01 or placebo on Day 0 and at the deltoid muscle in the upper arm and tested for safety; tolerance and immunogenicity as per the schedule described in the study protocol.;Group W: One-dose 50-ug elder (>=60 years) group:All the subjects are administrated V-01 or placebo on Day 0 at the deltoid muscle in the upper arm and tested for safety; tolerance and immunogenicity as per the schedule described in the study protocol.;", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "10\u03bcg;2;Days0-21;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "25\u03bcg;2;Days0-21;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "50\u03bcg;1;18-59 years and >=60 years", "treatment_id": 1086, "treatment_name": "Recombinant sars-cov-2 fusion protein vaccine (v-01)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]